[STUDY_ID_REMOVED] 
 
Study ID: VOLUMA‐006 
 
 
 
Title: A multicenter, single‐blind, randomized, controlled study of th e safety and effectiveness of 
JUVÉDERM VOLUMA® XC injectable gel for chin augmentation 
 
Statistical Analysis Plan Date : 28 Feb 2017 
 
 
Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
1. Title Page 
STATISTICAL ANALYSIS PLAN 
A multicenter, single-blind, randomized, contro lled study of the safety and effectiveness of 
JUVÉDERM VOLUMA® XC injectable gel for chin augmentation  
Draft 1.0: 2017-02-28  
 
Study Number: VOLUMA-006 
Development Phase: Pivotal 
Product Name: JUVÉDERM VOL UMA XC Injectable  
Study Statistician: . 
Sponsor: Allergan, Inc.  
2525 Dupont Drive, 
Irvine, CA 92612  
 
 
 This document is the property of Allergan, Inc.  and may not, in full or part, be passed on, 
reproduced, published, distributed to any person,  or submitted to any regulatory authority 
without the express written permission of Allergan, Inc.

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
2. Table of Contents 
1. Title Page  .............................................................................................................................. ... 1 
2. Table of Contents  ..................................................................................................................... 2 
2.1 List of Tables  .................................................................................................................. 3 
   
3. List of Abbreviations and Definition of Terms  ........................................................................ 6 
4. Introduction  ..............................................................................................................................  7 
4.1 Study Design Summary  ................................................................................................. 7 
   
4.1.2 Number of Participants  ...................................................................................... 8 
4.2 Study Objectives and Endpoints  .................................................................................... 9 
   
5. Statistical Methodology and Study Endpoints  ....................................................................... 15 
5.1 Statistical and Analytical Plans  .................................................................................... 15 
5.1.1 Common Conventions  ...................................................................................... 15 
5.1.1.1 Analysis Populations  ......................................................................... 15 
5.1.1.2 Study Treatments  ............................................................................... 15 
5.1.1.3 Statistical Methodology  ..................................................................... 15 
5.1.1.4 Missing Data  ...................................................................................... 16 
5.1.1.5 Site Pooling  ....................................................................................... 16  
5.1.2 Demographics  .................................................................................................. 17  
5.1.2.1 Analysis Populations  ......................................................................... 17 
5.1.2.2 Subject Disposition  ............................................................................ 17 
5.1.2.3 Protocol Deviations  ........................................................................... 18 
5.1.2.4 Demographics  .................................................................................... 18 
5.1.2.5 Baseline Characteristics  .................................................................... 19 
5.1.2.6 Medical History  ................................................................................. 19 
5.1.2.7 Prior and Concomitant Medications  .................................................. 19 
5.1.2.8 Exposure to Study Treatment  ............................................................ 20 
5.1.2.9 Administration of Study Treatment  ................................................... 20 
5.1.3 Effectiveness Analyses  ..................................................................................... 20 
5.1.3.1 Primary Effectiveness Endpoint  ........................................................ 21 
5.1.3.2 Secondary Effectiveness Endpoint  .................................................... 22 
   
5.1.4 Safety Analyses  ................................................................................................ 23 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
5.1.4.1 Study Treatment Exposure and Compliance  ..................................... 24 
5.1.4.2 Adverse Events  .................................................................................. 24 
   
   
   
   
   
   
   
 
5.1.6 Interim Analyses ............................................................................................... 27 
5.2 Determination of Sample Size  ..................................................................................... 28 
5.3 Changes in the Conduct of the Study or Planned Analyses  ......................................... 28 
6. Data Handling and Analysis Conventions  ............................................................................. 29 
6.1 Analysis Days  .............................................................................................................. 29 
   
6.2.1 Effectiveness .................................................................................................... 30 
6.2.2 Safety ............................................................................................................... 31 
6.3 Missing/Incomplete Date Conventions  ........................................................................ 31 
6.3.1 Missing/Incomplete AE Start Date  .................................................................. 31 
6.3.2 Missing/Incomplete AE  End Date  ................................................................... 32 
6.4 Imputed Value Listing Conventions  ............................................................................. 32 
 
  
 
 
 
2.1 List of Tables 
Table 3-1  Abbreviations and Definitions of Terms  ................................................................. 6 
   
  

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
 
 
 
 
   
 
 
Table 5-1  Analysis Populations  ............................................................................................. 15 
Table 5-2 Statistical Methodology ........................................................................................ 15 
Table 5-3  Missing Data Handling by Endpoint Type ............................................................ 16 
Table 5-4  Analysis Population Summaries ........................................................................... 17 
Table 5-5  Subject Disposition Summaries  ............................................................................ 17 
Table 5-6  Protocol Deviation Summary  ................................................................................ 18 
Table 5-7  Demographic Summaries  ...................................................................................... 18 
Table 5-8  Baseline Characteristics Summaries  ..................................................................... 19 
Table 5-9  Medical History  .................................................................................................... 19 
Table 5-10  Medication  ............................................................................................................ 19 
Table 5-11  Exposure to Study Treatment  ................................................................................ 20 
Table 5-12  Administration of Study Treatment  ...................................................................... 20 
Table 5-13  Effectiveness Assessments  .................................................................................... 21 
Table 5-14  Effectiveness Endpoint Baseline Definitions  ........................................................ 21 
Table 5-15  Primary Effectiveness Analyses  ............................................................................ 21 
Table 5-16  Secondary Effectiveness Analyses  ........................................................................ 21 
   
Table 5-18  AE Terms  .............................................................................................................. 21 
Table 5-19  AE Summaries  ...................................................................................................... 21 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
   
   
   
   
   
   
Table 5-26  Sample Size Assumptions  ..................................................................................... 28 
Table 6-1  Analysis Day Definitions  ...................................................................................... 29 
 
 
 
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
3. List of Abbreviations and Definition of Terms 
Table 3-1 Abbreviations and Definitions of Terms 
Abbreviation/Term Definition 
3D 3-dimensional  
ACRS Allergan Chin Retrusion Scale  
ADE Adverse Device Effect  
AE Adverse Event  
CFR Code of Federal Regulations  
CI Confidence Interval  
eCRF Electronic Case Report Form  
EI Evaluating Investigator  
DFU Directions For Use  
FDA Food and Drug Administration  
  
GAIS Global Aesthetic Improvement Scale  
HA Hyaluronic Acid  
HIPAA Health Insurance Portabi lity and Accountability Act  
IC Informed Consent  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IRB Institutional Review Board  
ISO International Organizatio n for Standardization  
ISR Injection Site Response  
ITT Intent-to-treat  
IWRS Interactive Web Response System  
mITT modified Intent-To-Treat  
PP Per-Protocol  
PT Preferred Term  
SADE Serious Adverse Device Effect  
SOC System Organ Class  
TI Treating Investigator  
UADE Unanticipated Adverse Device Effect  
US United States  

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
4. Introduction 
This statistical analysis plan (SAP) details comprehensive, technical specifications of the 
statistical analyses of the effectiveness and safety  data outlined and/or sp ecified in the protocol 
of Study VOLUMA-006 (Amendment 4 version date d 2017-03-01).  This SAP will be approved 
prior to database lock.  
 
4.1 Study Design Summary 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
4.1.2 Number of Participants 
Up to 224 subjects will be enrolled at up to 15 sites. 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
4.2 Study Objectives and Endpoints 
The objectives of this study are to evaluate  the safety and effectiveness of JUVÉDERM 
VOLUMA XC injectable gel in augmentation of chin retrusion in adult subjects seeking 
improvement in chin volume deficit. 
 
Each study primary objective, secondary objecti ve, and other objectives are presented with 
corresponding endpoint(s) below: 
Table 4-1 Study Objectives and Corresponding Endpoints 
Objectives Endpoints 
 
  • To evaluate and compare the effectiveness  of JUVÉDERM VOLUMA XC injectable 
gel with no treatment control in 
augmentation of chin retrusion in adult subjects seeking improvement in chin 
volume deficit 
 
 
 
  
 
  
 
 
 
• To evaluate the safety of JUVÉDERM VOLUMA XC injectable gel in 
augmentation of chin retrusion in adult 
subjects seeking improvement in chin volume deficit Primary Endpoint :   
• Responder rate based on photo assessment of the 
Allergan Chin Retrusion Scale (ACRS) at month 6 
Secondary Endpoints: 
• Change from baseline in overall scores of the 
Satisfaction with Chin module of the FACE-Q 
questionnaire at month 6 
• Responder rate based on Evaluating Investigator (EI) assessment of global aesthetic improvement 
scale (GAIS) in the chin area at month 6  
• Responder rate based on subject assessments of the GAIS in the chin area at month 6 
 
  
 
 
 
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
5. Statistical Methodology and Study Endpoints 
5.1 Statistical and Analytical Plans 
Statistical analyses will be conducte d using  
 
5.1.1 Common Conventions 
5.1.1.1 Analysis Populations 
The analysis populations will consist of subjects as defined below: 
Table 5-1 Analysis Populations 
Population Definition Study Treatment 
Intent-to-Treat (ITT) All randomiz ed subjects Randomized assignment 
Modified Intent-to-
Treat (mITT) • All subjects randomized to the treatment (treatment group) 
who receive at least 1 study treatment  
• All subjects randomized to the control group  Randomized assignment 
Per-Protocol (PP) population
 All mITT subjects who do not have any significant protocol deviations affecting the primary effectiveness endpoint Randomized assignment 
Safety • All subjects randomized to the treatment (treatment group) 
who receive at least 1 study device treatment  
• All subjects randomized to the control group Actual received 
 
Unless specified otherwise, all effectiveness an alyses will be performe d on the mITT population  
using the “as-randomized” assignment for each subj ect (ie, if a subject randomized to the 
control group is treated inadvert ently at the start of the study, the assessments for that subject 
will nonetheless be included in the control group analysis). The ITT and PP populations will be 
used to perform sensitivity analyses for the primary effectiveness variable. All safety analyses 
will be conducted using the safety population. 
 
5.1.1.2 Study Treatments 
The following treatment groups are defined for this study: 
• Study Treatment:  JUVÉDERM VO LUMA XC injectable gel 
• Control Treatment:  Delayed treatment 
 
 
 
5.1.1.3 Statistical Methodology 
The methodologies defined below apply as specified to individual endpoints defined in this SAP.  

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
Table 5-2 Statistical Methodology 
Methodology Description 
Categorical counts • Number and percent of subjec ts in individual categories 
o Subjects with ≥ 1qualifying event counted once per individual category 
o N included = participants with non-missing value for by visit analysis 
Event descriptives • Number and percentage of even ts in individual categories 
o Events counted individually for each instance 
• Percentage denominator = total number of events 
Continuous 
descriptives • N included, mean, standard deviation (SD), median, minimum, maximum 
• N included = subjects with non-missing value 
CFB descriptives • Continuous descriptives for baseline, postbaseline, and change from baseline (CFB) values 
• N included = subjects with non-missing values at both baseline and the specified postbaseline analysis visit 
CFB Paired T • Continuous descriptives for baseline, postbaseline, and CFB values 
o P-values from a 2-sided paired t-test comparing baseline and postbaseline values  
• N included = subjects with non-missing values at both baseline and the specified postbaseline analysis visit 
Responder • Categorical descriptives for responders and nonresponders 
o Include count and percent along with exact binomial 95% CI 
o P-values from 2-sided Fisher’s exact test  
• N included = with non-missing values at both baseline and the specified postbaseline 
analysis visit 
 
 
5.1.1.4 Missing Data 
General missing data handling conventions are specified and summarized as follows: 
Table 5-3 Missing Data Ha ndling by Endpoint Type 
Endpoint type  Timing Missing Data Handling 
Responder  M onth 6 (no-
treatment control period) • All subjects included (ITT population) 
• Multiple imputation with 5 imputed datasets is applied to subjects with no postbaseline va lues using the below model: 
 
Month 6 ACRS = ߚ
଴+ߚଵBaseline ACRS + ߚଶMonth 1 ACRS + 
ߚଷMonth 3 ACRS 
where ACRS score is based on photo assessment. 
Responder  M onth 6 (no-
treatment control 
period)  All subject included (ITT population) 
 Last observation carried forward (LOCF) for subjects with no postbaseline values 
 
The above missing data handling conventions will only be used for sensitivity analysis of the 
primary effectiveness endpoint.  
 
5.1.1.5 Site Pooling 
The impact of investigational sites on the primary effectiveness analysis at Month 6 will be evaluated by including investigational site, tr eatment assignment, and their interaction as 
Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
predictor variablies in a multivariate logistic re gression analysis with response status on the 
ACRS as the dependent variable. Investigationa l sites with few enrolled subjects may be pooled 
with other sites based on subjects  enrolled, geographical region, or other site characteristics. The 
interaction between site and treatment will be co nsidered significant if the p-value of this 
interaction is less than 0.05.  
 
5.1.2 Demographics 
5.1.2.1 Analysis Populations 
The distribution of subjects within the analys is populations will be summarized as follows: 
Table 5-4 Analysis Population Summaries 
Endpoint Description Timing Methodology 
All Consented  Distribution of all randomized, 
Randomized but Discontinued Before 
Treatment, Not Randomized (with Reason 
for Randomization Failure) Screening period  Listing 
Not Randomized  List of not randomized subjects with 
randomization failure reasons Screening period  Listing 
ITT, mITT, PP and 
Safety populations Distribution in total and by treatment group After randomization Categorical counts 
 
5.1.2.2 Subject Disposition 
Subject disposition encompasses the distribut ion of subjects who enter, complete, and 
discontinue during each specified  analysis period (i.e., screen ing and treatment periods), along 
with eCRF-reported discontinuation reasons from each respective analysis period. A subject in 
the treatment group is considered a completer if s/he completes the month 12 visit without 
receiving repeat treatment or completes the mont h 1 visit after receiving repeat treatment. A 
subject in the control group is considered a completer if s/he completes the month 6 visit without 
receiving optional treatment or completes the month 6 visit after receiving optional treatment. 
Subject disposition will be summarized as follows: 
Table 5-5 Subject Disposition Summaries 
Endpoint Description Timing Methodology 
Study disposition Distribution in the randomized subjects in 
total and by treatment group Month 6 and final Categorical counts 
 
Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
5.1.2.3 Protocol Deviations 
Protocol deviations will  be defined in a separate document, including importance classification. 
Protocol deviations will be summarized as follows: 
Table 5-6 Protocol Deviation Summary 
Endpoint Description Timing Methodology 
Important protocol 
deviations Important protocol deviation will be listed — Categorical counts/ 
Listing 
  
5.1.2.4 Demographics 
Demographics will be summarized for mITT population in total and by treatment group as 
follows: 
Table 5-7 Demographic Summaries 
Endpoint Description Timing Methodology 
Age Age (years) relative to informed consent 
date Informed consent Continuous 
descriptives 
Sex, race, and ethnicity o Sex 
o Female 
o Male 
o Race  
o White 
o Black or African 
American 
o Asian 
o American Indian or Alaska Native  
o Native Hawiaan or Other 
Pacific Islander 
• Ethnicity 
o Hispanic or Latino 
o Not Hispanic or Latino Screening Period Categorical counts 
 
 
 
 
 
 
Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
5.1.2.5 Baseline Characteristics 
Baseline characteristics will be summarized in  total and by treatment group for the mITT 
population as follows: 
Table 5-8 Baseline Characteristics Summaries 
Endpoint Timing Methodology 
• Sun exposure (hours per day) 
• Duration of Smoking Latest assessment prior to 
randomization Continuous descriptives 
• Fitzpatrick Skin Phototype 
o I, II, III, IV, V, VI 
• Smoking history Latest assessment prior to 
randomization Categorical counts 
 
5.1.2.6 Medical History 
Medical history, encompassing abnormalities, surgeries, and cosmetic procedures reported as 
occurring before the Screening Visit, will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA), version 18.1 or newer. Uni que subjects who report medical history events 
will be presented as subject listing for the Safety Population. 
Table 5-9 Medical History  
Endpoint Timing Methodology 
Abnormalities and surgeries occurring 
before the Screening Visit Screening Period Listing 
 
 
5.1.2.7 Prior and Concomitant Medications 
Medications will be coded using the World Health Organization (WHO) Drug Dictionary, 
version March 2014 or newer. Unique subjec ts who reported medications (Anatomical 
Therapeutic Chemical (ATC) 4 class and PT) will be presented as subjec t listing for the Safety 
Population. 
Table 5-10 Medication  
Endpoint Description Timing Methodology 
Prior medications Medications taken before the study 
treatment start date and time for the 
treatment group and before randomization 
date and time for the control group, regardless of medication end date Screening Period 
prior to 
treatment/randomiza
tion  Listing 
Concomitant 
medications during 
control period Medications taken on or after the study 
treatment start date and time for the 
treatment group and after randomization 
date and time but before optional treatment 
date time (at month 6) for the control Control Period Listing 
Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
Endpoint Description Timing Methodology 
group, regardless of medication end date 
Concomitant 
medications during treatment period Medications taken  on or after the study treatment start date and time for both control and treatment groups, regardless of 
medication start date Treatment Period   
 Listing 
 
 
5.1.2.8 Exposure to Study Treatment 
Treatment exposure related variable will be summarized for safety population by treatment group 
as follows: 
Table 5-11 Exposure to Study Treatment  
Endpoint Description Timing Methodology 
Volume injected Initial, Touch-up,  Combined initial and 
touch-up, Repeat  Treament period Continuous 
descriptives 
 
 
5.1.2.9 Administration of Study Treatment 
Variables related to administration of treatm ent will be summarized for safety population by 
treatment group as follows: 
Table 5-12 Administration of Study Treatment  
Endpoint Description Timing Methodology 
• Pretreatment 
Anesthesia type 
• Planes of injection 
• Injection technique 
• Needle/cannula used 
• Injection ease 
• Product moldability 
 Initial, Touch-up, Repeat (Repeat for Treatmemt Group 
only) Treatment period Categorical counts 
Pretreatment Anesthesia duration Initial, Touch-up, Repeat (Repeat for Treatmemt Group 
only) Treament period Continuous 
descriptives 
 
 
5.1.3 Effectiveness Analyses 
Effectiveness analyses will be based on the mITT Population. 
The following effectiveness assessments are defined: 
Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
Table 5-13 Effectiveness Assessments 
Assessment Description 
Chin retrusion based on photo 
assessment Assessed by EI using the 5-point ACRS (see Appendix A). The EI will assess 2D profile images of the left side of the chin rendered by the Canfield image analysis 
technician from the 3D images. 
Chin retrusion based on live 
assessment EI’s live ACRS assessment 
Global Aesthetic Improvement Scale (GAIS) Assessments by subject and EI based on 5-point GAIS (see Appendix B) 
Satisfaction with Chin 
module Assessed by subject response on the Satisfaction with Chin module of the validated FACE-Q questionnaire (see Appendix C) 
  
 
 
  
  
  
 
Baseline assessments for applicable effec tiveness endpoints are defined as follows: 
Table 5-2 Effectiveness Endpoint Baseline Definitions 
Endpoint Description Timing 
• Chin retrusion based on photo 
assessment 
 Baseline refers to the photo evaluation by EI at 
randomization (or screening if no usable 
assessment is available at randomization)  Randomization/ 
Screening 
• Chin retrusion based on live assessment Baseline refers to the joint live evaluation by EI 
and TI at randomization (or screening if no usable assessment is available at 
randomization)  Randomization/ 
Screening 
• Satisfaction with Chin module 
  Baseline refers to the evaluation at screening  Screening 
  
  
   
 
 
5.1.3.1 Primary Effectiveness Endpoint 
The primary effectiveness endpoint will be met if the responder rate at month 6 for the treatment 
group is statistically greater than that for the control group at month 6 and the observed 
responder rate at month 6 for the treatment group is greater than 50%. A responder is a subject 
who shows clinically significant improvement, i.e., ≥ 1-point decrease, on the ACRS from 
baseline based on EI assessment of 2D  renderings of the chin profile.  
The primary effectiveness analysis is summarized in Table 5-15. 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
Table 5-15 Primary Effectiveness Analyses 
Endpoint Description Timing Methodology 
Primary: Responder analysis 
based on photo ACRS  • Superiority of the treatment group over no-treatment control group 
• Responder rate of treatment group is greater than 50% Month 6 Responder 
 
The primary effectiveness analysis will be performed on the mITT population without any 
missing data imputation. Sensitivity analysis will be performed using ITT and PP populations as 
well as using missing data handling conventions as decribed in Section 5.1.1.1.4. Additionally, 
sensitivity analysis will be performed on mITT subjects with a baseline ACRS photo score of 2 
or 3.  
5.1.3.2 Secondary Effectiveness Endpoint 
The secondary effectiveness analysis  is summarized in Table 5-16. 
Table 5-16 Secondary Ef fectiveness Analyses 
Endpoint Description Timing Methodology
Secondary 1: Responder 
analysis based on GAIS (by 
EI and by subject) Summary for treatment group Month 6 Categorical 
Secondary 2: Satisfaction 
with Chin module using overall score Comparison of baseline vs. postbaseline for treatment group using 2-sided paired t-test Month 6 CFB Paired T 
A responder on GAIS is a subject who shows improve ment in the overall aesthetic assessment in 
the chin area (corresponds to  a response of “Improved” or “Much Improved” on GAIS). 
The secondary effectiveness analysis for Sa tisfaction with Chin module of the FACE-Q 
questionnaire will be conducted only if the prim ary endpoint is met. No additional multiplicity 
adjustment or gatekeeping multiple comparisons procedures are needed. 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
5.1.4 Safety Analyses 
Safety analyses will be based on the Safety Population. 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
5.1.4.1 Study Treatment Exposure and Compliance 
See section 5.1.1.2.8. 
5.1.4.2 Adverse Events 
The following adverse event (AE) terms are defined: 
Table 5-18 AE Terms 
Term Description 
Treatment-
emergent 
Adverse Event (TEAE) Treatment group: An event that initially occurs or increases in severity on or after the treatment 
start date. Control group: An event that initially occurs or increases in severity on or after randomization 
date. 
 
AEs and encompassing abnormalities, reported as o ccurring after the Screening Visit, will be 
coded using MedDRA version 18.1 or newer. A lis ting for all TEAEs in the treatment and control 
groups will be presented. Additionally, unique su bjects reporting AEs as well as the number of 
events in the following AE categories will be summarized for treatment subjects, control subjects 
after optional treatment, and all treated subjects as follows: 
Table 5-3 AE Summaries 
Endpoint Description Timing Methodology 
Overall summary Overall summary only for the following 
categories: 
• Treatment-emergent AEs 
(TEAEs) 
• Treatment-related TEAEs 
• Treatment-related TEAEs at 
injection site 
• Treatment-related TEAEs not at 
injection site 
• All Serious AEs (SAE) 
• Treatment-related SAE 
• Discontinued due to TEAE 
• Deaths Treatment period Categorical counts, 
Event descriptives 
TEAEs • Overall summary and by SOC, PT and severity Treatment  period Categorical counts, 
Event descriptives 
Treatment-related 
TEAEs • Overall summary and by SOC, PT and severity 
• Overall summary by severity, 
duration, time to onset, resolution, 
and treatment required Treatment period Categorical counts, 
Event descriptives 
SAEs Overall summary and by PT Treatment Period Listing 
AEs leading to 
discontinuation Overall summary and by PT Treatment Period Listing 
Note: SOCs will be sorted alphabetically; PTs will be so rted in descending frequency in the treatment group. 
AEs for control group before and after optional treatment are summarized separately. 
 
Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
Time to onset for TEAEs will be computed as  
AE start date - reference date + 1, 
where, the reference date is initial treatment date for TEAEs occurri ng on or after initial 
treatment but before touch-up treatment and the reference date is touch-up treatment date for 
TEAEs occurring on or after touch-up treatment but before repeat treatment. 
Duration for TEAEs will be computed as AE end date – AE start date + 1. 
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
5.1.6 Interim Analyses 
No interim analysis will be performed.  
 
 
 
 
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
5.2 Determination of Sample Size 
The sample size assumptions and estimate are summarized as follows: 
Table 5-4 Sample Size Assumptions 
Parameter Assumption / Estimate 
Primary endpoint Chin retrusion assessment responder  
Risk difference1 40 (80% Voluma vs 40% Control) 
SD NA 
α 5% 
Sides 2 
Power  >99% 
N per group 120 in Voluma group, 40 in control group 
Screen Fail Rate 15% 
Drop-out Rate 15% 
N total 224 
1 Based on literature/previous study VOLUMA-002 and relevant details. 
 
 
5.3 Changes in the Conduct of the Study or Planned Analyses 
Prior to database lock, there were no changes in study conduct or planne d analyses (except per 
protocol analysis) from what was described in  the protocol and detailed in the SAP. No 
unplanned analyses were conducted, and the planned analyses were  conducted following 
database lock. 
 
 
Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
6. Data Handling and Analysis Conventions 
6.1 Analysis Days 
Treatment Day for effectiveness,  and AE are defined as follows: 
Table 6-1 Analysis Day Definitions 
Term Description 
Effectiveness 
 
Effectiveness Day Treatment Group and Control Group (only the control subjects receiving optional 
treatment): 
Relative to the last treatment date (either the initial treatment, if no touch-up is performed, 
or the touch-up treatment) 
o Effectiveness Day = analysis date – last treatment start date + 1 
o Effectiveness Day 1 = last treatment start date 
 
Control (before receiving  optional treatment): 
Relative to the randomization date 
o Effectiveness Day = analysis date –randomization date +1 
o Effectiveness Day 1 = randomization date 
 
Safety (including AE 
 
Safety Day  Treatment Group and Treated Control (i.e., only the control subj ects receiving optional 
treatment): 
Relative to treatmentdate (initial and touch-up) 
Safety Day = analysis date – initial treatment date + 1 
Safety Day 1 = initial treatment date 
 
Control (before receiving  optional treatment): 
Relative to the randomization date 
o Safety Day = analysis date – randomization date +1 
o Safety Day 1 = randomization date 
 Treatment Group Only: 
Relative to the repeat treatment date (after repeat treatment) 
Safety Day = analysis date – repeat treatment date + 1 
Safety Day 1 = repeat treatment date
 
 
6.2 Analysis Visit Windows 
All scheduled and unscheduled vi sits with complete dates will  be assigned visit windows and 
used for analysis. However, if a scheduled visit with incomplete date is available with no other 
visits with complete date during the visit window , then the visit with incomplete date may be 
used for analysis and the nominal visit will be used as the visit window (e.g., if the only 
assessment collected for Month 6 visit window is on a Month 6 CRF with incomplete date, then 
those data will be used for the Month 6 assessments). 
If there are multiple visits occurring within a si ngle visit window with relevant data, the visit 
closest to the target day will be used in the analysis of the corresponding visit windows. If 2 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
visits are equal distance to the target day and are th e same type of visit, then the later visit will be 
used. 
Analysis visit windows for effectiveness e ndpoints and safety are defined as follows: 
6.2.1 Effectiveness 
The analysis visit windows for effectiveness endpoints are defined as follows: 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
  
  
  
6.2.2 Safety 
No analysis visit windows are required for TEAEs . Analysis visit windows will only be 
used for summarizing . For the treatment group, refer to 
table 6.2 for analysis visit windows  For the control 
group in the control period (i.e., no treatment period) refer to ta ble 6.3 and for the control group 
in the treatment period refer to table 6.2.   
6.3 Missing/Incomplete Date Conventions 
6.3.1 Missing/Incomplete AE Start Date 
Imputation of dates with missing day and/or m onth is only applied to TEAEs.  If adequate 
information is available, no imputation is needed. TEAE start dates with missing day or month will be imputed as following: 
• If day and month are missing but year is available, then the imputed day and month will 
be 01 Jan or the initial treatment date if th ey have the same year, whichever is later 
(because TEAE onset is not expected prio r to administration of study treatment) 
• If day is missing but the month and year are available, then the imputed day will be the 
first day of the month or the in itial injection date if they have the same month and year, 
whichever is later 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
6.3.2 Missing/Incomplete AE  End Date 
Imputation of dates with missing day and/or m onth is only applied to TEAEs.  If adequate 
information is available, no imputation is n eeded. TEAE end dates with missing day or month 
will be imputed as following: 
• If day and month are missing but year is available, then the imputed day and month will 
be 31 Dec or the study exitdate if they have the same year, whichever is earlier  
If day is missing but the month and year are available, then the imputed day will be the last day of the month or the study exit date if they have the same month and year, whichever is earlier 
 
6.4 Imputed Value Listing Conventions 
In general, listings will present the actual partial or missing values rather than the imputed values that may be used in endpoint derivation. In in stances where imputed values will be presented, 
imputed values will be flagged. Actual rules will be fully defined in the table, figure, and data listing specification document. 
 
 
 
 
 
  
  
Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
Appendix A: Allergan Chin Retrusion Scale 
Table 1: Allergan Chin Retrusion Scale (ACRS) 
Score Grade Description 
0 None No chin retrusion; Chin midpoint* at or in front of the lower vermilion 
border vertical line 
1 Minimal Minimal chin retrusion; Chin midpoint* is between the labiomental sulcus 
vertical line and lower vermilion border vertical line 
2 Moderate Moderate chin retrusion; Chin midpoint* at labiomental sulcus vertical line 
3 Severe Sever chin retrusion; Chin midpoint* slightly behind labiomental sulcus 
vertical line 
4 Extreme Extreme chin retrusion*; Chin midpoint significantly behind labiomental 
sulcus vertical line 
* Chin midpoint: the midpoint between the labiomental sulcus and the inferior point of the chin 
Figure 1: Lines Used in the ACRS Descriptiors 
 
 
 
 
 
 
 
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
 
  
 
 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 

Allergan Confidential SAP VOLUMA-006   
JUVÉDERM VOLUMA® XC 
 

ALLERGAN  
 
 
 
 
    
 
 
 
 
      
                   
                  
                         
                         
                         
                         
                         
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
                      
 Statistical Analysis Plan
